NASDAQ · ELOX
Eloxx Pharmaceuticals, Inc.
$13.45+$0.27 (+2.05%)
Eloxx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.52% below the high.
Loading market information…
OTC · CDXI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cardax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cardax, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity. This product is primarily distributed through online sales and wholesale channels. The company is also progressing two pharmaceutical candidates: CDX-101, an astaxanthin-derived drug candidate intended to address cardiovascular inflammation and dyslipidemia, with a primary focus on severe hypertriglyceridemia; and CDX-301, a zeaxanthin-based pharmaceutical currently under development for macular degeneration. Cardax, Inc. maintains its headquarters in Honolulu, Hawaii.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:15 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$13.45+$0.27 (+2.05%)
Eloxx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.52% below the high.
$0.05$0.00 (0.0%)
Micron Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.2% below the high.
$0.00$0.00 (0.0%)
MetaStat Inc’s quoted price sits in the lower half of its reported 52-week range, 98.71% below the high.
$0.00$0.00 (0.0%)
Modern Technology Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Cannabiz Mobile, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.02% below the high.
$0.00$0.00 (0.0%)
Verde Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
Nabriva Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
MedAvail Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
